# Prolonged Daily Temozolomide for Low-Grade Glioma

> **NCT00165360** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 46 (actual)

## Conditions studied

- Glioma
- Astrocytoma
- Oligodendroglioma

## Interventions

- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00165360
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** 2006-12
- **Final completion:** 2009-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2009-11-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165360, "Prolonged Daily Temozolomide for Low-Grade Glioma". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00165360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*